fbpx
Size of letters 1x
Site color
Image
Additionally
Line height
Letter spacing
Font
Embedded items (videos, maps, etc.)
 

The Manager of the Health Care Committee of the EBA participated in a forum dedicated to the MTA system

08/ 10/ 2024
  Olena Sytenok, Manager of the Health Care Committee of the European Business Association, joined the forum, where several important issues regarding the functioning of the Medical Technology Assessment (MTA) system in Ukraine were discussed. MTA is a crucial tool for making decisions about the rational use of public funds in the healthcare system. The MTA process for pharmaceuticals in Ukraine was initiated in 2020, and despite existing challenges, the system continues to operate. However, the MTA for medical devices is just beginning to be developed in Ukraine, while it has been actively used worldwide for a long time. During her speech, Olena Sytenok emphasized the importance of implementing the MTA system for medical devices while simultaneously creating a list of medical devices that will be reimbursed from the state budget. On one hand, this will ensure transparency and clarity regarding the significance of this procedure for medical device manufacturers, and on the other hand, it will allow patients to receive quality medical devices that improve their quality of life free of charge. However, it is crucial to provide a sufficient transition period before implementing such a list to prevent restricting patient access to medical devices currently procured by the state under the Cabinet of Ministers of Ukraine Resolution No. 216 of March 7, 2022, On Certain Issues of Procurement of Medicines, Medical Devices, and Related Supplies. It is important to note that medical devices differ significantly from pharmaceuticals in terms of their life cycle, and regulatory environment, and even within medical devices, there is great diversity. Therefore, they require a separate approach in the application of MTA that considers these features. The MTA methodology should take into account not only the immediate impact on the budget at a specific point in time but also clinical effectiveness, safety, and the long-term economic impact that disability caused by a long-term illness can have, as well as the effect of the illness on the patients quality of life. Ms. Olena also pointed out that it would be advisable to involve the business community in developing the draft guidelines for MTA for medical devices before it is presented for official public discussion so that EBA members can provide their expertise to align this document with European standards. The EBA sincerely thanks the organizers for the invitation and hopes for continued active cooperation with stakeholders on these issues.
01/
Olena Sytenok, Manager of the Health Care Committee of the European Business Association, joined the forum, where several important issues regarding the functioning of the Medical Technology Assessment (MTA) system in Ukraine were discussed.

MTA is a crucial tool for making decisions about the rational use of public funds in the healthcare system. The MTA process for pharmaceuticals in Ukraine was initiated in 2020, and despite existing challenges, the system continues to operate. However, the MTA for medical devices is just beginning to be developed in Ukraine, while it has been actively used worldwide for a long time.

During her speech, Olena Sytenok emphasized the importance of implementing the MTA system for medical devices while simultaneously creating a list of medical devices that will be reimbursed from the state budget. On one hand, this will ensure transparency and clarity regarding the significance of this procedure for medical device manufacturers, and on the other hand, it will allow patients to receive quality medical devices that improve their quality of life free of charge. However, it is crucial to provide a sufficient transition period before implementing such a list to prevent restricting patient access to medical devices currently procured by the state under the Cabinet of Ministers of Ukraine Resolution No. 216 of March 7, 2022, “On Certain Issues of Procurement of Medicines, Medical Devices, and Related Supplies.”

It is important to note that medical devices differ significantly from pharmaceuticals in terms of their life cycle, and regulatory environment, and even within medical devices, there is great diversity. Therefore, they require a separate approach in the application of MTA that considers these features.

The MTA methodology should take into account not only the immediate impact on the budget at a specific point in time but also clinical effectiveness, safety, and the long-term economic impact that disability caused by a long-term illness can have, as well as the effect of the illness on the patient’s quality of life.

Ms. Olena also pointed out that it would be advisable to involve the business community in developing the draft guidelines for MTA for medical devices before it is presented for official public discussion so that EBA members can provide their expertise to align this document with European standards.

The EBA sincerely thanks the organizers for the invitation and hopes for continued active cooperation with stakeholders on these issues.

If you have found a spelling error, please, notify us by selecting that text and pressing Ctrl+Enter.

Start
in the Telegram bot
Read articles. Share in social networks

Spelling error report

The following text will be sent to our editors: